The state of Arkansas and Arkansas 340B covered entities separately asked a federal appeals court yesterday to back a judge’s decision in December that the state’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the
…
Articles by : Tom Mirga, Editor at Large
The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar bottom lines.”
…
U.S. Senate Health, Education, Labor, and Pensions Committee staff members reportedly have decided to exclude 340B issues from a bipartisan drug policy bill they are writing behind the scenes in order to preserve the bill’s odds of being passed next
…
A Virginia Democrat and South Dakota Republican this afternoon reintroduced bipartisan legislation in the U.S. House to protect 340B covered entities and contract pharmacies from discrimination by insurers and pharmacy benefit managers.
Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.)
…
Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.
If the court disagrees,
…
Two Republican U.S. senators expressed concerns about pharmacy benefit manager encroachment on 340B covered entity savings during a Senate Finance Committee hearing on PBMs last week.
“I often hear concerns from South Dakota hospitals and health centers when it comes
…
Requiring hospitals to report what they make from 340B drug discounts versus what they spend on charity care could be a first step toward tackling full-scale 340B program reform later, a senior Republican on the U.S. House committee with jurisdiction
…
UPDATE Friday, March 31, 2023, 6:45 p.m. EDT—Story updated with comment from the National Association of Community Health Centers.
Drug manufacturer GlaxoSmithKline this afternoon announced a major expansion of its conditions on 340B pricing in the contract
…
Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.
Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer
…